Timing of Initiating Glycopeptide Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: The Impact on Clinical Outcome
Table 2
Variables associated with 14-day overall mortality.
Variable
Yes, No. (%)
No, No. (%)
P-value
No. of patients
56 (16.5)
283 (83.5)
Age in years, median (range)
68 (38–98)
65 (22–93)
0.45
Gender, male
33 (58.9)
181 (63.9)
0.55
Underlying disease/condition
Cardiovascular disease
10 (17.9)
39 (13.8)
0.41
Diabetes mellitus
30 (53.6)
107 (37.8)
0.04
Uremia requiring dialysis
10 (17.9)
56 (19.8)
0.85
Decompensated liver cirrhosis
10 (17.9)
37 (13.1)
0.40
Malignancies
9 (16.1)
55 (19.4)
0.71
Prosthetic device implantation
6 (10.7)
35 (12.4)
0.83
Severity-of-illness markera
Nosocomial acquisition
46 (82.1)
199 (70.3)
0.07
Intensive care unit admission
16 (28.6)
59 (20.8)
0.22
APACHE II score, median (range)
18 (1–31)
17 (2–38)
0.19
APACHE II score > 15
13 (23.2)
31 (10.9)
0.03
Source of infectionb
Catheter-related infection
1 (1.8)
39 (13.8)
<0.01
Endovascular infection
0
9 (3.2)
0.37
Soft-tissue infection
10 (17.9)
79 (27.9)
0.42
Osteomyelitis
12 (21.4)
55 (19.4)
0.72
Urinary tract infection
0
4 (1.4)
1.00
Pneumonia
20 (35.7)
31 (10.9)
<0.01
Primary bacteremia
10 (17.9)
64 (21.8)
0.48
Timing of initiating glycopeptide therapy
Before preliminary BC report indicated SLO growth and within 24 h after BC indicated SLO growth
36 (64.3)
155 (54.8)
0.24
BC: blood culture; MRSA: methicillin-resistant S. aureus; No.: number; SLO: Staphylococcus-like organism.
aAt time of blood culture sampling.
bSome patients had more than one infected site.
